Filtern
Dokumenttyp
Sprache
- Englisch (2)
Referierte Publikation
- ja (2)
Schlagworte
- Aza-BODIPY (1)
- Boron compound (1)
- LIBS (1)
- Laser induced plasma (1)
- NIR-I (1)
- Nanoparticle formation (1)
- Optical imaging (1)
- Plasma diagnostics (1)
- Plasma modeling (1)
- SWIR (1)
- Theranostic (1)
Organisationseinheit der BAM
In this paper experimental temperature and density maps of the laser induced plasma in water during Pulsed Laser ablation in Liquid (PLAL) for the production of metallic nanoparticles (NPs) has been determined. A detection system based on the simultaneous acquisition of two emission images at 515 and 410 nm has been constructed and the obtained images have been processed simultaneously by imaging software. The results of the data analysis show a variation of the temperature between 4000 and 7000 K over the plasma volume. Moreover, by the study of the temperature distribution and of the number densities along the plasma expansion axis it is possible to observe the condensation zone of the plasma where NPs can be formed.
Finally, the time associated to the electron processes is estimated and the plasma charging effect on NPs is demonstrated. The set of observations retrieved from these experiments suggests the importance of the plasma phase for the growth of NPs and the necessity of considering the spatial distribution of plasma parameters for the understanding of one of the most important issues of the PLAL process, that is the source of solid material in the plasma phase.
Boron neutron capture therapy (BNCT) is a radiotherapeutic modality based on the nuclear capture of slow neutrons by stable 10B atoms followed by charged particle Emission that inducing extensive damage on a very localized level (<10 um). To be effcient, a suffcient amount of 10B should accumulate in the tumor area while being almost cleared from the normal surroundings. A water-soluble aza-boron-dipyrromethene dyes (BODIPY) fluorophore was reported to strongly accumulate in the tumor area with high and BNCT compatible Tumor/Healthy Tissue ratios.
The clinically used 10B-BSH (sodium borocaptate) was coupled to the water-soluble aza-BODIPY platform for enhanced 10B-BSH tumor vectorization. We demonstrated a strong uptake of the compound in tumor cells and determined its biodistribution in mice-bearing tumors. A model of chorioallantoic membrane-bearing glioblastoma xenograft was developed to evidence the BNCT potential of such compound, by subjecting it to slow neutrons. We demonstrated the Tumor accumulation of the compound in real-time using optical imaging and ex vivo using elemental imaging based on laser-induced breakdown spectroscopy. The tumor growth was significantly reduced as compared to BNCT with 10B-BSH. Altogether, the fluorescent aza-BODIPY/10B-BSH compound is able to vectorize and image the 10B-BSH in the tumor area, increasing its theranostic potential for effcient approach of BNCT.